<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00130247</url>
  </required_header>
  <id_info>
    <org_study_id>01-009</org_study_id>
    <secondary_id>TBRU 8</secondary_id>
    <nct_id>NCT00130247</nct_id>
  </id_info>
  <brief_title>Tuberculosis Treatment Shortening Trial</brief_title>
  <official_title>A Prospective Study of Shortening the Duration of Standard Short Course Chemotherapy From 6 Months to 4 Months in HIV-non-infected Patients With Fully Drug-Susceptible, Non-cavitary Pulmonary Tuberculosis With Negative Sputum Cultures After 2 Months of Anti-TB Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      Tuberculosis (TB) is a serious infection that can affect the lungs and other parts of the
      body. The usual way to treat TB is to take 4 medicines by mouth every day for 2 months, then
      take 2 of the same medicines for 4 more months, for a total of 6 months. The purpose of this
      study is to see if taking 4 months of TB medicines is as effective in curing some TB patients
      as taking 6 months of TB medicines. Study participants will include 758 human
      immunodeficiency virus (HIV)-non-infected individuals, ages 18-60. Participants will be
      treated with 4 standard drugs called isoniazid, rifampicin, pyrazinamide and ethambutol. All
      individuals will take TB medicines for at least 4 months. After 4 months of treatment, if no
      TB germs are growing in sputum samples, participants will be assigned to either stop taking
      TB medicine (4 months of treatment) or to continue taking TB drugs for 2 more months (6
      months of treatment). Participants will be involved in study procedures for up to 30 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tuberculosis (TB) is a major global health problem. TB is the current leading cause of death
      due to an identifiable infectious agent worldwide. One of the highest priorities for
      tuberculosis control programs is to shorten anti-TB treatment while maintaining its
      effectiveness. Current 6-month short course chemotherapy regimens are over 95% effective for
      the treatment of tuberculosis when fully administered. Six months is a long time, however,
      and patients frequently discontinue anti-TB treatment once their symptoms have improved. The
      duration of standard short course chemotherapy is one of the major obstacles to its
      successful application and poses substantial challenges to programs with respect to patient
      adherence, program resource needs, and logistical requirements for directly observed therapy.
      The primary objective of this study is to assess the efficacy of shortening anti-TB treatment
      to 4 months in human immunodeficiency virus (HIV)-non-infected adults with drug-susceptible,
      non-cavitary pulmonary tuberculosis who convert their sputum culture to negative after 2
      months of treatment. Secondary objectives of this study include: comparing pre-treatment
      sputum bacillary load in patients with and without cavitary disease; compare time after
      inoculation of BACTEC or Mycobacteria growth indicator tube (MGIT) liquid culture media until
      positive with semi-quantitative sputum acid fast bacteria (AFB) smear and culture on solid
      media as measures of pre-treatment sputum bacillary load; and determining the influence of
      immunologic characteristics of subjects pre-treatment, during treatment and at the end of
      therapy on rate of bacillary clearance and risk for relapse. A total of 758 HIV-non-infected
      adults, male or female, 18-60 years of age, with newly diagnosed initial episodes of sputum
      AFB smear-positive or -negative, culture-positive, non-cavitary, drug-susceptible pulmonary
      TB who are sputum culture negative after 2 months of anti-TB treatment will be randomly
      assigned to complete a total of 4 or 6 months of anti-TB therapy. The experimental regimen
      will include a total of 4 months of anti-TB treatment [2 months of daily isoniazid (INH),
      rifampicin, pyrazinamide and ethambutol followed by 2 months of daily INH and rifampicin].
      The comparative regimen will include a total of 6 months standard short course anti-TB
      chemotherapy (2 months of daily INH, rifampicin, pyrazinamide and ethambutol followed by 4
      months of daily INH and rifampicin). Subjects will be involved in study related procedures
      for approximately 30 months after beginning the initial anti-TB treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bacteriologic or Clinical Relapse at 30 Months After Onset of Initial Anti-tuberculosis (TB) Treatment - Intention-to-treat</measure>
    <time_frame>30 months</time_frame>
    <description>Patients who presented with TB after completion of study phase treatment but before the end of follow-up were classified as relapses. A bacteriologic relapse was defined as a patient who became consistently culture-positive [defined as at least 1 of the following]: (a) at least 1 sputum mycobacterial culture growing at least 10 colonies of MTB on solid medium; (b) 2 or more respiratory secretion cultures that are positive for MTB in liquid media; or (c) any culture from an extrapulmonary site that is positive for MTB during follow-up after successful completion of initial anti-TB treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bacteriologic or Clinical Relapse at 30 Months After Onset of Initial Anti-TB Treatment - Per-protocol</measure>
    <time_frame>30 months</time_frame>
    <description>Patients who presented with TB after completion of study phase treatment but before the end of follow-up were classified as relapses. A bacteriologic relapse was defined as a patient who became consistently culture-positive [defined as at least 1 of the following]: (a) at least 1 sputum mycobacterial culture growing at least 10 colonies of MTB on solid medium; (b) 2 or more respiratory secretion cultures that are positive for MTB in liquid media; or (c) any culture from an extrapulmonary site that is positive for MTB during follow-up after successful completion of initial anti-TB treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Failures or Relapses at 2 Years After Completion of TB Treatment: Intention to Treat</measure>
    <time_frame>2 years</time_frame>
    <description>A culture-positive treatment failure was defined as initial culture conversion but subsequent reversion to culture positivity. A clinical treatment failure was defined as a patient with clinical and/or radiographic evidence of progressive tuberculosis not confirmed by a positive culture after 4 or more months of anti-TB treatment while still receiving treatment. Patients who defaulted before completing study treatment and returned later with culture-positive tuberculosis were termed failures after non-adherence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Failures or Relapses at 2 Years After Completion of TB Treatment: Per Protocol</measure>
    <time_frame>2 years</time_frame>
    <description>A culture-positive treatment failure was defined as initial culture conversion but subsequent reversion to culture positivity. A clinical treatment failure was defined as a patient with clinical and/or radiographic evidence of progressive tuberculosis not confirmed by a positive culture after 4 or more months of anti-TB treatment while still receiving treatment. Patients who defaulted before completing study treatment and returned later with culture-positive tuberculosis were termed failures after non-adherence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapses at 1 and 2 Years</measure>
    <time_frame>1 and 2 years after successful completion of initial anti-TB treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acquired Drug Resistance in Patients Who Relapsed</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunologic: Changes in Cytokine Levels in Mycobacterium Tubercolosis (MTB) Antigen-stimulated Whole Blood Culture Supernatants - Results Are Pending</measure>
    <time_frame>After 2 and 6 months of anti-TB treatment and upon relapse</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunologic: Store Peripheral Blood Mononuclear Cells (PBMC) - Results Are Pending</measure>
    <time_frame>Pre-treatment and serum pre-treatment after 2 and 6 months of anti-TB treatment, and at the time of relapse for future immunologic analysis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunologic: Changes in Sputum Cytokine Levels - Results Are Pending</measure>
    <time_frame>After 1 and 2 months of anti-TB treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiologic: Changes in Sputum Mycobacterial mRNA - Results Are Pending</measure>
    <time_frame>At 1 and 2 months of anti-TB treatment, and upon relapse</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiologic: Time After Inoculation Until Culture Positive in BACTEC 460 or MGIT 960 Enriched Liquid Media After 2 Months in Treatment - Results Are Pending</measure>
    <time_frame>Months 1, 2, 3, 4, 5, 6, 9, 12, 15, 18, 24, and 30</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">394</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>2EHRZ/2HR arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily treatment with isoniazid (INH), rifampicin, ethambutol and pyrazinamide for 2 months followed by 2 months of daily INH plus rifampicin over a maximum time period of 18 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2EHRZ/4HR arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily treatment with Isoniazid (INH), rifampicin, ethambutol and pyrazinamide for 2 months followed by 4 months of daily INH plus rifampicin over a maximum time period of 28 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrazinamide</intervention_name>
    <description>1st line bactericidal agent; dosages are 15-30 mg/kg/d, up to 2 grams (gm)/d.</description>
    <arm_group_label>2EHRZ/2HR arm</arm_group_label>
    <arm_group_label>2EHRZ/4HR arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
    <description>1st line bactericidal agent which inhibits deoxyribonucleic acid (DNA)-dependent ribonucleic acid (RNA) polymerase; dosages are 10 mg/kg/d (up to 600 mg/d).</description>
    <arm_group_label>2EHRZ/2HR arm</arm_group_label>
    <arm_group_label>2EHRZ/4HR arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoniazid</intervention_name>
    <description>Hydrazide of isonicotininc acid; antimicrobial activity is limited to mycobacteria where it inhibits the synthesis of mycolic acids.</description>
    <arm_group_label>2EHRZ/2HR arm</arm_group_label>
    <arm_group_label>2EHRZ/4HR arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethambutol</intervention_name>
    <description>Mycobacteriostatic agent given to prevent emergence of drug resistance to other 1st line drugs; dosages are 15-25 milligram (mg)/ kilogram (kg)/day (d).</description>
    <arm_group_label>2EHRZ/2HR arm</arm_group_label>
    <arm_group_label>2EHRZ/4HR arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults, male or female, aged 18-60.

          -  Newly diagnosed initial episodes of pulmonary tuberculosis. Sputum smear-positive and
             -negative patients are eligible for enrollment. The diagnosis of tuberculosis must be
             confirmed by culture. Acid fast bacteria (AFB) smear positive patients found later not
             to have tuberculosis (TB) (i.e. those with non-tuberculous mycobacterial disease) and
             those without culture confirmation [at least one culture on solid media growing &gt; 10
             colonies of Mycobacterium tuberculosis (MTB) or a positive BACTEC or Mycobacteria
             growth indicator tube (MGIT) enriched liquid culture growing MTB] will be removed from
             the study.

          -  Chest X-ray and clinical findings consistent with tuberculosis.

          -  Hemoglobin greater than or equal to 8 gm/dL (greater than or equal to 5.0 mmol/L).

          -  Serum creatinine &lt; 2 mg/dL (&lt; 177 micro mol/L).

          -  Serum aspartate aminotransferase (AST) &lt; 1.5 times the upper limit of normal for the
             testing laboratory, and serum total bilirubin &lt; 1.3 mg/dL (22.2 micro mol/L).

          -  Random serum glucose less than or equal to 150 mg/dl (8.3 mmol/L).

          -  Ambulatory.

          -  Willing to provide informed consent for study participation, provide required
             specimens for examination, and to undergo and receive results of human
             immunodeficiency virus (HIV) testing.

          -  Willing to receive supervised anti-TB treatment.

          -  Completion of the required 112 doses of chemotherapy within 18 weeks of starting
             treatment.

        Exclusion Criteria:

          -  Human immunodeficiency virus (HIV)-infected.

          -  History of prior tuberculosis or history of previous tuberculosis treatment.

          -  Pregnant or breastfeeding.

          -  Cavitary tuberculosis on initial chest X-ray (taken within 14 days of study entry).

          -  Exposure to person(s) with known drug resistant tuberculosis.

          -  Patients receiving chronic steroids or other immunosuppressive medications.

          -  Extra-pulmonary tuberculosis.

          -  Patients with drug resistant tuberculosis (resistance to isoniazid (INH), rifampicin,
             pyrazinamide or ethambutol).

          -  Professional sex worker, alcoholic and/or intravenous (IV) drug abuser.

          -  Silicosis or other serious chronic medical problems including diabetes mellitus or
             chronic renal failure.

        Final determination of eligibility will be made after review of drug susceptibility testing
        results on an initial sputum isolate and results of all sputum cultures.

        Pregnant patients may not be enrolled in the study. Patients in the 4 month arm who become
        pregnant during months 5 and 6 of study participation will be dropped from the study and
        receive an additional 2 months of treatment with INH and rifampicin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universidade Federal do Espirito Santo/HUCAM</name>
      <address>
        <city>Vitoria</city>
        <zip>29040-091</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Makati Medical Center</name>
      <address>
        <city>Makati City</city>
        <zip>1229</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tuberculosis Research Control Center, Mulago Hospital</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Philippines</country>
    <country>Uganda</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Johnson JL, Thiel BA. Time until relapse in tuberculosis treatment trials: implication for phase 3 trial design. Am J Respir Crit Care Med. 2012 Sep 1;186(5):464.</citation>
    <PMID>22942350</PMID>
  </reference>
  <results_reference>
    <citation>Palaci M, Dietze R, Hadad DJ, Ribeiro FK, Peres RL, Vinhas SA, Maciel EL, do Valle Dettoni V, Horter L, Boom WH, Johnson JL, Eisenach KD. Cavitary disease and quantitative sputum bacillary load in cases of pulmonary tuberculosis. J Clin Microbiol. 2007 Dec;45(12):4064-6. Epub 2007 Oct 10.</citation>
    <PMID>17928422</PMID>
  </results_reference>
  <results_reference>
    <citation>Maciel EL, Brioschi AP, Peres RL, Guidoni LM, Ribeiro FK, Hadad DJ, Vinhas SA, Zandonade E, Palaci M, Dietze R, Johnson JL. Smoking and 2-month culture conversion during anti-tuberculosis treatment. Int J Tuberc Lung Dis. 2013 Feb;17(2):225-8. doi: 10.5588/ijtld.12.0426.</citation>
    <PMID>23317958</PMID>
  </results_reference>
  <results_reference>
    <citation>Johnson JL, Hadad DJ, Dietze R, Maciel EL, Sewali B, Gitta P, Okwera A, Mugerwa RD, Alcaneses MR, Quelapio MI, Tupasi TE, Horter L, Debanne SM, Eisenach KD, Boom WH. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med. 2009 Sep 15;180(6):558-63. doi: 10.1164/rccm.200904-0536OC. Epub 2009 Jun 19.</citation>
    <PMID>19542476</PMID>
  </results_reference>
  <results_reference>
    <citation>Bark CM, Dietze R, Okwera A, Quelapio MI, Thiel BA, Johnson JL. Clinical symptoms and microbiological outcomes in tuberculosis treatment trials. Tuberculosis (Edinb). 2011 Nov;91(6):601-4. doi: 10.1016/j.tube.2011.05.007. Epub 2011 Aug 2.</citation>
    <PMID>21813327</PMID>
  </results_reference>
  <results_reference>
    <citation>Bark CM, Thiel BA, Johnson JL. Pretreatment time to detection of Mycobacterium tuberculosis in liquid culture is associated with relapse after therapy. J Clin Microbiol. 2012 Feb;50(2):538. doi: 10.1128/JCM.06193-11. Epub 2011 Nov 23.</citation>
    <PMID>22116143</PMID>
  </results_reference>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2005</study_first_submitted>
  <study_first_submitted_qc>August 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2005</study_first_posted>
  <results_first_submitted>August 20, 2009</results_first_submitted>
  <results_first_submitted_qc>December 23, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 27, 2010</results_first_posted>
  <last_update_submitted>January 31, 2013</last_update_submitted>
  <last_update_submitted_qc>January 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tuberculosis, Uganda, Brazil, Philippines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Isoniazid</mesh_term>
    <mesh_term>Pyrazinamide</mesh_term>
    <mesh_term>Ethambutol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>HIV-uninfected 18 to 60 year old adults with suspected or newly diagnosed pulmonary tuberculosis were eligible for enrollment at participating sites in Kampala, Uganda; Vit√≥ria, Brazil; and Manila/Makati City, the Philippines. Screening began in April 2002 in Uganda, December 2002 in Brazil, and November 2003 in the Philippines.</recruitment_details>
      <pre_assignment_details>Subjects who met eligibility criteria were started on standard chemotherapy and routinely followed during anti-TB therapy. Patients with drug-susceptible TB who were sputum culture negative after 2 months of treatment were randomly assigned at 4 months to stop treatment or received an additional 2 months of daily isoniazid (INH) and rifampicin.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>4-Month Arm</title>
          <description>Daily treatment with INH, rifampicin, ethambutol and pyrazinamide for 2 months followed by 2 months of daily INH plus rifampicin over a maximum time period of 18 weeks.</description>
        </group>
        <group group_id="P2">
          <title>6-Month Arm</title>
          <description>Daily treatment with INH, rifampicin, ethambutol and pyrazinamide for 2 months followed by 4 months of daily INH plus rifampicin over a maximum time period of 28 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="196"/>
                <participants group_id="P2" count="198"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="194"/>
                <participants group_id="P2" count="194"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Post-randomization exclusion</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not compliant with DOT</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>4-Month Arm</title>
          <description>Daily treatment with INH, rifampicin, ethambutol and pyrazinamide for 2 months followed by 2 months of daily INH plus rifampicin over a maximum time period of 18 weeks.</description>
        </group>
        <group group_id="B2">
          <title>6-Month Arm</title>
          <description>Daily treatment with INH, rifampicin, ethambutol and pyrazinamide for 2 months followed by 4 months of daily INH plus rifampicin over a maximum time period of 28 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="196"/>
            <count group_id="B2" value="198"/>
            <count group_id="B3" value="394"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="196"/>
                    <measurement group_id="B2" value="198"/>
                    <measurement group_id="B3" value="394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.2" spread="10"/>
                    <measurement group_id="B2" value="30.3" spread="10"/>
                    <measurement group_id="B3" value="30.8" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Philippines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uganda</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bacteriologic or Clinical Relapse at 30 Months After Onset of Initial Anti-tuberculosis (TB) Treatment - Intention-to-treat</title>
        <description>Patients who presented with TB after completion of study phase treatment but before the end of follow-up were classified as relapses. A bacteriologic relapse was defined as a patient who became consistently culture-positive [defined as at least 1 of the following]: (a) at least 1 sputum mycobacterial culture growing at least 10 colonies of MTB on solid medium; (b) 2 or more respiratory secretion cultures that are positive for MTB in liquid media; or (c) any culture from an extrapulmonary site that is positive for MTB during follow-up after successful completion of initial anti-TB treatment.</description>
        <time_frame>30 months</time_frame>
        <population>The intention to treat (ITT) analysis included all 394 fully eligible and randomized patients allocated to the shortened 4-month treatment group (N=196) or the standard 6-month treatment group (N=198). There were no allocated patients excluded in the ITT analysis dataset.</population>
        <group_list>
          <group group_id="O1">
            <title>4-Month Arm</title>
            <description>Daily treatment with INH, rifampicin, ethambutol and pyrazinamide for 2 months followed by 2 months of daily INH plus rifampicin over a maximum time period of 18 weeks.</description>
          </group>
          <group group_id="O2">
            <title>6-Month Arm</title>
            <description>Daily treatment with INH, rifampicin, ethambutol and pyrazinamide for 2 months followed by 4 months of daily INH plus rifampicin over a maximum time period of 28 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Bacteriologic or Clinical Relapse at 30 Months After Onset of Initial Anti-tuberculosis (TB) Treatment - Intention-to-treat</title>
          <description>Patients who presented with TB after completion of study phase treatment but before the end of follow-up were classified as relapses. A bacteriologic relapse was defined as a patient who became consistently culture-positive [defined as at least 1 of the following]: (a) at least 1 sputum mycobacterial culture growing at least 10 colonies of MTB on solid medium; (b) 2 or more respiratory secretion cultures that are positive for MTB in liquid media; or (c) any culture from an extrapulmonary site that is positive for MTB during follow-up after successful completion of initial anti-TB treatment.</description>
          <population>The intention to treat (ITT) analysis included all 394 fully eligible and randomized patients allocated to the shortened 4-month treatment group (N=196) or the standard 6-month treatment group (N=198). There were no allocated patients excluded in the ITT analysis dataset.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of binomial proportion of relapse: Intention-to-treat</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This two-sided equivalence trial compared the efficacy of 4 and 6 months of treatment. We assumed that the risk of relapse for patients in the 6 month arm was 3.5% and that an absolute difference of 5% (i.e. relapse rate of 8.5%) was clinically meaningful. For a level of significance of 0.05 and 80% power (two sided), we estimated that 284 evaluable subjects per arm were required.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.051</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
            <estimate_desc>Confidence interval for difference of binomial proportions adjusted with Hauck Anderson continuity correction.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Failures or Relapses at 2 Years After Completion of TB Treatment: Intention to Treat</title>
        <description>A culture-positive treatment failure was defined as initial culture conversion but subsequent reversion to culture positivity. A clinical treatment failure was defined as a patient with clinical and/or radiographic evidence of progressive tuberculosis not confirmed by a positive culture after 4 or more months of anti-TB treatment while still receiving treatment. Patients who defaulted before completing study treatment and returned later with culture-positive tuberculosis were termed failures after non-adherence.</description>
        <time_frame>2 years</time_frame>
        <population>The intention to treat (ITT) analysis included all 394 fully eligible and randomized patients allocated to the shortened 4-month treatment group (N=196) or the standard 6-month treatment group (N=198). There were no allocated patients excluded in the ITT analysis dataset.</population>
        <group_list>
          <group group_id="O1">
            <title>4-Month Arm</title>
            <description>Daily treatment with INH, rifampicin, ethambutol and pyrazinamide for 2 months followed by 2 months of daily INH plus rifampicin over a maximum time period of 18 weeks.</description>
          </group>
          <group group_id="O2">
            <title>6-Month Arm</title>
            <description>Daily treatment with INH, rifampicin, ethambutol and pyrazinamide for 2 months followed by 4 months of daily INH plus rifampicin over a maximum time period of 28 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Failures or Relapses at 2 Years After Completion of TB Treatment: Intention to Treat</title>
          <description>A culture-positive treatment failure was defined as initial culture conversion but subsequent reversion to culture positivity. A clinical treatment failure was defined as a patient with clinical and/or radiographic evidence of progressive tuberculosis not confirmed by a positive culture after 4 or more months of anti-TB treatment while still receiving treatment. Patients who defaulted before completing study treatment and returned later with culture-positive tuberculosis were termed failures after non-adherence.</description>
          <population>The intention to treat (ITT) analysis included all 394 fully eligible and randomized patients allocated to the shortened 4-month treatment group (N=196) or the standard 6-month treatment group (N=198). There were no allocated patients excluded in the ITT analysis dataset.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Failures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relapses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Failures or Relapses at 2 Years After Completion of TB Treatment: Per Protocol</title>
        <description>A culture-positive treatment failure was defined as initial culture conversion but subsequent reversion to culture positivity. A clinical treatment failure was defined as a patient with clinical and/or radiographic evidence of progressive tuberculosis not confirmed by a positive culture after 4 or more months of anti-TB treatment while still receiving treatment. Patients who defaulted before completing study treatment and returned later with culture-positive tuberculosis were termed failures after non-adherence.</description>
        <time_frame>2 years</time_frame>
        <population>The per-protocol analysis included all 370 patients (185 per treatment arm) who received the intervention, completed treatment and full follow-up and did not have exogenous reinfection of TB. The 24 excluded subjects included 2 patients with exogenous reinfection of TB, 12 lost to follow-up, 4 deaths, and 6 who did not receive the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>4-Month Arm</title>
            <description>Daily treatment with INH, rifampicin, ethambutol and pyrazinamide for 2 months followed by 2 months of daily INH plus rifampicin over a maximum time period of 18 weeks.</description>
          </group>
          <group group_id="O2">
            <title>6-Month Arm</title>
            <description>Daily treatment with INH, rifampicin, ethambutol and pyrazinamide for 2 months followed by 4 months of daily INH plus rifampicin over a maximum time period of 28 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Failures or Relapses at 2 Years After Completion of TB Treatment: Per Protocol</title>
          <description>A culture-positive treatment failure was defined as initial culture conversion but subsequent reversion to culture positivity. A clinical treatment failure was defined as a patient with clinical and/or radiographic evidence of progressive tuberculosis not confirmed by a positive culture after 4 or more months of anti-TB treatment while still receiving treatment. Patients who defaulted before completing study treatment and returned later with culture-positive tuberculosis were termed failures after non-adherence.</description>
          <population>The per-protocol analysis included all 370 patients (185 per treatment arm) who received the intervention, completed treatment and full follow-up and did not have exogenous reinfection of TB. The 24 excluded subjects included 2 patients with exogenous reinfection of TB, 12 lost to follow-up, 4 deaths, and 6 who did not receive the intervention.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Failures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relapses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relapses at 1 and 2 Years</title>
        <time_frame>1 and 2 years after successful completion of initial anti-TB treatment</time_frame>
        <population>Analysis includes the 386 patients who received the intervention, completed treatment, and started post-treatment follow-up (193 patients in each treatment arm). Two subjects were lost after completing treatment and contributed no follow-up time, and 6 subjects did not receive the intervention so were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>4-Month Arm</title>
            <description>Daily treatment with INH, rifampicin, ethambutol and pyrazinamide for 2 months followed by 2 months of daily INH plus rifampicin over a maximum time period of 18 weeks.</description>
          </group>
          <group group_id="O2">
            <title>6-Month Arm</title>
            <description>Daily treatment with INH, rifampicin, ethambutol and pyrazinamide for 2 months followed by 4 months of daily INH plus rifampicin over a maximum time period of 28 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Relapses at 1 and 2 Years</title>
          <population>Analysis includes the 386 patients who received the intervention, completed treatment, and started post-treatment follow-up (193 patients in each treatment arm). Two subjects were lost after completing treatment and contributed no follow-up time, and 6 subjects did not receive the intervention so were not included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Relapses at 1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relapses at 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Rate of relapse at 1 year. All patients adherent with treatment and remaining in follow-up at 1 year were included in the calculation of the relapse incidence rate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Incidence rate ratio</param_type>
            <param_value>3.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>12.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Rate of relapse at 2 years. All patients adherent with treatment and remaining in follow-up at 2 years were included in the calculation of the relapse incidence rate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Incident rate ratio</param_type>
            <param_value>4.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.29</ci_lower_limit>
            <ci_upper_limit>15.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acquired Drug Resistance in Patients Who Relapsed</title>
        <time_frame>2 years</time_frame>
        <population>This analysis was per protocol and looked for acquired drug resistance among the 13 patients in the 4-Month Arm who relapsed and the 3 patients in the 6-Month Arm who relapsed.</population>
        <group_list>
          <group group_id="O1">
            <title>4-Month Arm</title>
            <description>Daily treatment with INH, rifampicin, ethambutol and pyrazinamide for 2 months followed by 2 months of daily INH plus rifampicin over a maximum time period of 18 weeks.</description>
          </group>
          <group group_id="O2">
            <title>6-Month Arm</title>
            <description>Daily treatment with INH, rifampicin, ethambutol and pyrazinamide for 2 months followed by 4 months of daily INH plus rifampicin over a maximum time period of 28 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Acquired Drug Resistance in Patients Who Relapsed</title>
          <population>This analysis was per protocol and looked for acquired drug resistance among the 13 patients in the 4-Month Arm who relapsed and the 3 patients in the 6-Month Arm who relapsed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunologic: Changes in Cytokine Levels in Mycobacterium Tubercolosis (MTB) Antigen-stimulated Whole Blood Culture Supernatants - Results Are Pending</title>
        <time_frame>After 2 and 6 months of anti-TB treatment and upon relapse</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunologic: Store Peripheral Blood Mononuclear Cells (PBMC) - Results Are Pending</title>
        <time_frame>Pre-treatment and serum pre-treatment after 2 and 6 months of anti-TB treatment, and at the time of relapse for future immunologic analysis</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunologic: Changes in Sputum Cytokine Levels - Results Are Pending</title>
        <time_frame>After 1 and 2 months of anti-TB treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiologic: Changes in Sputum Mycobacterial mRNA - Results Are Pending</title>
        <time_frame>At 1 and 2 months of anti-TB treatment, and upon relapse</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bacteriologic or Clinical Relapse at 30 Months After Onset of Initial Anti-TB Treatment - Per-protocol</title>
        <description>Patients who presented with TB after completion of study phase treatment but before the end of follow-up were classified as relapses. A bacteriologic relapse was defined as a patient who became consistently culture-positive [defined as at least 1 of the following]: (a) at least 1 sputum mycobacterial culture growing at least 10 colonies of MTB on solid medium; (b) 2 or more respiratory secretion cultures that are positive for MTB in liquid media; or (c) any culture from an extrapulmonary site that is positive for MTB during follow-up after successful completion of initial anti-TB treatment.</description>
        <time_frame>30 months</time_frame>
        <population>The per-protocol analysis included all 370 patients (185 per treatment arm) who received the intervention, completed treatment and full follow-up and did not have exogenous reinfection of TB. The 24 excluded subjects included 2 patients with exogenous reinfection of TB, 12 lost to follow-up, 4 deaths, and 6 who did not receive the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>4-Month Arm</title>
            <description>Daily treatment with INH, rifampicin, ethambutol and pyrazinamide for 2 months followed by 2 months of daily INH plus rifampicin over a maximum time period of 18 weeks.</description>
          </group>
          <group group_id="O2">
            <title>6-Month Arm</title>
            <description>Daily treatment with INH, rifampicin, ethambutol and pyrazinamide for 2 months followed by 4 months of daily INH plus rifampicin over a maximum time period of 28 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Bacteriologic or Clinical Relapse at 30 Months After Onset of Initial Anti-TB Treatment - Per-protocol</title>
          <description>Patients who presented with TB after completion of study phase treatment but before the end of follow-up were classified as relapses. A bacteriologic relapse was defined as a patient who became consistently culture-positive [defined as at least 1 of the following]: (a) at least 1 sputum mycobacterial culture growing at least 10 colonies of MTB on solid medium; (b) 2 or more respiratory secretion cultures that are positive for MTB in liquid media; or (c) any culture from an extrapulmonary site that is positive for MTB during follow-up after successful completion of initial anti-TB treatment.</description>
          <population>The per-protocol analysis included all 370 patients (185 per treatment arm) who received the intervention, completed treatment and full follow-up and did not have exogenous reinfection of TB. The 24 excluded subjects included 2 patients with exogenous reinfection of TB, 12 lost to follow-up, 4 deaths, and 6 who did not receive the intervention.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This two-sided equivalence trial compared the efficacy of 4 and 6 months of treatment. We assumed that the risk of relapse for patients in the 6 month arm was 3.5% and that an absolute difference of 5% (i.e. relapse rate of 8.5%) was clinically meaningful. For a level of significance of 0.05 and 80% power (two sided), we estimated that 284 evaluable subjects per arm were required.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.054</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>0.10</ci_upper_limit>
            <estimate_desc>Confidence interval for difference of binomial proportions adjusted with Hauck Anderson continuity correction.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiologic: Time After Inoculation Until Culture Positive in BACTEC 460 or MGIT 960 Enriched Liquid Media After 2 Months in Treatment - Results Are Pending</title>
        <time_frame>Months 1, 2, 3, 4, 5, 6, 9, 12, 15, 18, 24, and 30</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 years</time_frame>
      <desc>Patients reported adverse events at scheduled or unscheduled visits. Adverse event forms were completed by medical officers on site</desc>
      <group_list>
        <group group_id="E1">
          <title>4-Month Arm</title>
          <description>Daily treatment with INH, rifampicin, ethambutol and pyrazinamide for 2 months followed by 2 months of daily INH plus rifampicin over a maximum time period of 18 weeks.</description>
        </group>
        <group group_id="E2">
          <title>6-Month Arm</title>
          <description>Daily treatment with INH, rifampicin, ethambutol and pyrazinamide for 2 months followed by 4 months of daily INH plus rifampicin over a maximum time period of 28 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="196"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction (Death)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Coronary Arery Occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Glaucoma in Right Eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Panuveitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Gunshot Wound (Abdomen)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Gunshot Wound to Head (Death)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Suffocation (Death)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hospitalization (Unknown Cause of Abdominal Pain)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Other Acquired Calcaneus Deformity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Vocal Cord Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache (Severe Post-operative)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="77"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar Affective Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cystocele and Perineal Rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Endometrial Polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Fetal Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Ovarian Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Ovarian Teratoma (Benign)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pelvic Abcess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Pre-eclampsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Uterine Myoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Malignant Melanoma (Death)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical Intervention on Right Shoulder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Tracheal Plastic Repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="170" subjects_at_risk="196"/>
                <counts group_id="E2" subjects_affected="164" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <counts group_id="E1" events="19" subjects_affected="15" subjects_at_risk="196"/>
                <counts group_id="E2" events="19" subjects_affected="15" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="63" subjects_affected="48" subjects_at_risk="196"/>
                <counts group_id="E2" events="59" subjects_affected="49" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="20" subjects_affected="15" subjects_at_risk="196"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="31" subjects_affected="20" subjects_at_risk="196"/>
                <counts group_id="E2" events="41" subjects_affected="32" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="196"/>
                <counts group_id="E2" events="19" subjects_affected="16" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="148" subjects_affected="87" subjects_at_risk="196"/>
                <counts group_id="E2" events="103" subjects_affected="67" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="22" subjects_affected="17" subjects_at_risk="196"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Rigors</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="196"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="196"/>
                <counts group_id="E2" events="22" subjects_affected="17" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Flu</sub_title>
                <counts group_id="E1" events="63" subjects_affected="40" subjects_at_risk="196"/>
                <counts group_id="E2" events="46" subjects_affected="27" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="196"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Tinea Infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="196"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Appetite Lost</sub_title>
                <counts group_id="E1" events="49" subjects_affected="39" subjects_at_risk="196"/>
                <counts group_id="E2" events="35" subjects_affected="30" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" events="29" subjects_affected="24" subjects_at_risk="196"/>
                <counts group_id="E2" events="26" subjects_affected="20" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 10.1">Arthralgia</sub_title>
                <counts group_id="E1" events="92" subjects_affected="64" subjects_at_risk="196"/>
                <counts group_id="E2" events="87" subjects_affected="64" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="46" subjects_affected="34" subjects_at_risk="196"/>
                <counts group_id="E2" events="36" subjects_affected="31" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="196"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Pain in Limb</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="196"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="196"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="102" subjects_affected="64" subjects_at_risk="196"/>
                <counts group_id="E2" events="66" subjects_affected="46" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="196"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="115" subjects_affected="70" subjects_at_risk="196"/>
                <counts group_id="E2" events="77" subjects_affected="52" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Coryza</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="196"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="186" subjects_affected="104" subjects_at_risk="196"/>
                <counts group_id="E2" events="162" subjects_affected="90" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="196"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Produce Sputum</sub_title>
                <counts group_id="E1" events="57" subjects_affected="48" subjects_at_risk="196"/>
                <counts group_id="E2" events="50" subjects_affected="39" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Purulent Sputum</sub_title>
                <counts group_id="E1" events="40" subjects_affected="34" subjects_at_risk="196"/>
                <counts group_id="E2" events="33" subjects_affected="27" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" events="17" subjects_affected="12" subjects_at_risk="196"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="196"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="50" subjects_affected="33" subjects_at_risk="196"/>
                <counts group_id="E2" events="39" subjects_affected="27" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="196"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="57" subjects_affected="46" subjects_at_risk="196"/>
                <counts group_id="E2" events="52" subjects_affected="43" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="196"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Skin Lesion</sub_title>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="196"/>
                <counts group_id="E2" events="22" subjects_affected="9" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Enrollment was stopped early and the number of patients enrolled was 1/2 of the original sample size. The study was completed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>John L. Johnson, M.D., Principal Investigator</name_or_title>
      <organization>Case Western Reserve University, Tuberculosis Research Unit</organization>
      <phone>(216) 368-1949</phone>
      <email>jlj@case.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

